courtlistener_docket
134 records
Ma v. Teva Pharmaceuticals USA, Inc.
2026-06-03
Federal docket 1:26-cv-03108 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Stone v. Teva Pharmaceuticals USA, Inc.
2026-06-02
Federal docket 1:26-cv-03099 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Dugan v. Teva Pharmaceuticals USA, Inc.
2026-06-02
Federal docket 1:26-cv-03080 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Calderon v. Teva Pharmaceuticals USA, Inc.
2026-06-01
Federal docket 1:26-cv-03061 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Morales v. Teva Pharmaceuticals USA, Inc.
2026-06-01
Federal docket 1:26-cv-03060 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Burton v. Teva Pharmaceuticals USA, Inc.
2026-05-29
Federal docket 1:26-cv-03013 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Dinh v. Teva Pharmaceuticals USA, Inc.
2026-05-29
Federal docket 1:26-cv-02991 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Klebanowski v. Teva Pharmaceuticals USA, Inc.
2026-05-29
Federal docket 1:26-cv-02995 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Leak v. Teva Pharmaceuticals USA, Inc.
2026-05-29
Federal docket 1:26-cv-02993 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Cannamore v. Teva Pharmaceuticals USA, Inc.
2026-05-29
Federal docket 1:26-cv-02994 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Wright v. Teva Pharmaceuticals USA, Inc.
2026-05-29
Federal docket 1:26-cv-03014 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Grubaugh v. Teva Pharmaceuticals USA, Inc.
2026-05-29
Federal docket 1:26-cv-02992 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Ford v. Teva Pharmaceuticals USA, Inc.
2026-05-28
Federal docket 1:26-cv-02981 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Bueno v. Teva Pharmaceuticals USA, Inc.
2026-05-28
Federal docket 1:26-cv-02982 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Arling v. Teva Pharmaceuticals USA, Inc.
2026-05-28
Federal docket 1:26-cv-02949 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Blake v. Teva Pharmaceuticals USA, Inc.
2026-05-27
Federal docket 1:26-cv-02952 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Vasilenka v. Teva Pharmaceuticals USA, Inc.
2026-05-27
Federal docket 1:26-cv-02955 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Le v. Teva Pharmaceuticals USA, Inc.
2026-05-27
Federal docket 1:26-cv-02948 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Bowers v. Teva Pharmaceuticals USA, Inc.
2026-05-27
Federal docket 1:26-cv-02947 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Torres v. Teva Pharmaceuticals USA, Inc.
2026-05-27
Federal docket 1:26-cv-02951 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Lyons v. Teva Pharmaceuticals USA, Inc.
2026-05-27
Federal docket 1:26-cv-02950 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Zielinski v. Teva Pharmaceuticals USA, Inc.
2026-05-22
Federal docket 1:26-cv-02889 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Hischak v. Teva Pharmaceuticals USA, Inc.
2026-05-21
Federal docket 1:26-cv-02873 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Rigoni v. Teva Pharmaceuticals USA, Inc.
2026-05-20
Federal docket 1:26-cv-02833 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
McKinney v. Teva Pharmaceuticals USA, Inc.
2026-05-20
Federal docket 1:26-cv-02832 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Le v. Teva Pharmaceuticals USA, Inc.
2026-05-20
Federal docket 1:26-cv-02831 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Knight v. Teva Pharmaceuticals USA, Inc.
2026-05-19
Federal docket 1:26-cv-02814 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Anoushiravani v. Teva Pharmaceuticals USA, Inc.
2026-05-18
Federal docket 1:26-cv-02768 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Kirschenbaum v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02717 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Caven v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02715 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Glesing v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02702 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
O'Brien v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02716 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
French v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02714 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Gifford v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02719 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Beck v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02704 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Reza v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02720 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Bailey v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02713 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
McCormick v. Teva Pharmaceuticals USA, Inc.
2026-05-14
Federal docket 1:26-cv-02718 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Austin v. Teva Pharmaceuticals USA, Inc.
2026-05-13
Federal docket 1:26-cv-02699 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Banushi v. Teva Pharmaceuticals USA, Inc.
2026-05-12
Federal docket 1:26-cv-02656 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Karim v. Teva Pharmaceuticals USA, Inc.
2026-05-08
Federal docket 1:26-cv-02615 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Austin v. Teva Pharmaceuticals USA, Inc.
2026-05-08
Federal docket 1:26-cv-02623 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Sneed v. Teva Pharmaceuticals USA, Inc.
2026-05-07
Federal docket 1:26-cv-02584 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Amsalem v. Teva Pharmaceuticals USA, Inc.
2026-05-07
Federal docket 1:26-cv-02570 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Dialfonso v. Teva Pharmaceuticals USA, Inc.
2026-05-06
Federal docket 1:26-cv-02565 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Young v. Teva Pharmaceuticals USA, Inc.
2026-05-06
Federal docket 1:26-cv-02566 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Lopez v. Teva Pharmaceuticals USA, Inc.
2026-05-06
Federal docket 1:26-cv-02548 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Daly v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02532 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Anderson v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02522 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Gayle v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02523 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Jordan v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02528 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Carew v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02527 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Johnson v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02525 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Johnson v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02526 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Jahoda v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02531 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Walker v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02524 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Boyle v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02520 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Peretti v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02530 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Fertile v. Teva Pharmaceuticals USA, Inc.
2026-05-05
Federal docket 1:26-cv-02515 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Orlowski v. Teva Pharmaceuticals USA, Inc.
2026-05-04
Federal docket 1:26-cv-02492 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Nguyen v. Teva Pharmaceuticals USA, Inc.
2026-04-30
Federal docket 1:26-cv-02444 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Weiss v. Teva Pharmaceuticals USA, Inc.
2026-04-30
Federal docket 1:26-cv-02434 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Byrne v. Teva Pharmaceuticals USA, Inc.
2026-04-30
Federal docket 1:26-cv-02435 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Shelton v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02410 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Mainieri-Sanchez v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02400 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
DiGirolamo v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02412 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Sheppard v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02402 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Huff v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02392 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
El-Droubi v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02388 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Nardella v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02404 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Wager v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02407 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Narayan v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02397 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Stephens v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02403 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Martin v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02393 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Smith v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02405 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Hammond v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02395 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Ham v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02398 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Chhuom v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02406 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Denson v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02396 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Giesing v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02391 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Armand v. Teva Pharmaceuticals USA, Inc.
2026-04-29
Federal docket 1:26-cv-02401 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Robinson v. Teva Pharmaceuticals USA, Inc.
2026-04-28
Federal docket 1:26-cv-02369 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Speake v. Teva Pharmaceuticals USA, Inc.
2026-04-28
Federal docket 1:26-cv-02368 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Florez v. Teva Pharmaceuticals USA, Inc.
2026-04-27
Federal docket 1:26-cv-02327 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Harris v. Teva Pharmaceuticals USA, Inc.
2026-04-27
Federal docket 1:26-cv-02310 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Silva v. Teva Pharmaceuticals USA, Inc.
2026-04-24
Federal docket 1:26-cv-02301 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Aramburo v. Teva Pharmaceuticals USA, Inc.
2026-04-23
Federal docket 1:26-cv-02255 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Brooks v. Teva Pharmaceuticals USA, Inc.
2026-04-23
Federal docket 1:26-cv-02239 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Westrick v. Teva Pharmaceuticals USA, Inc.
2026-04-22
Federal docket 1:26-cv-02222 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Ware v. Teva Pharmaceuticals USA, Inc.
2026-04-22
Federal docket 1:26-cv-02207 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Ackerman v. Teva Pharmaceuticals USA, Inc.
2026-04-22
Federal docket 1:26-cv-02223 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Bond v. Teva Pharmaceuticals USA, Inc.
2026-04-22
Federal docket 1:26-cv-02208 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Sanborn v. Teva Pharmaceuticals USA, Inc.
2026-04-22
Federal docket 1:26-cv-02209 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Christie v. Teva Pharmaceuticals USA, Inc.
2026-04-20
Federal docket 1:26-cv-02147 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Porter v. Teva Pharmaceuticals USA, Inc.
2026-04-20
Federal docket 1:26-cv-02145 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
LITTLE v. TEVA PHARMACEUTICALS USA INC
2026-04-16
Federal docket 2:26-cv-04017 (njd); matched party 'TEVA PHARMACEUTICALS USA INC'
View Source
Simmons v. Teva Pharmaceuticals USA, Inc.
2026-04-15
Federal docket 1:26-cv-02067 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Stallings v. Teva Pharmaceuticals USA, Inc.
2026-04-14
Federal docket 1:26-cv-02039 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Dollan v. Teva Pharmaceuticals USA, Inc.
2026-04-14
Federal docket 1:26-cv-02038 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Ruiz v. Teva Pharmaceuticals USA, Inc.
2026-04-14
Federal docket 1:26-cv-02040 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Leith v. Teva Pharmaceuticals USA, Inc.
2026-04-08
Federal docket 1:26-cv-01894 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Moyer v. Teva Pharmaceuticals USA, Inc.
2026-04-06
Federal docket 1:26-cv-01844 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Fellman v. Teva Pharmaceuticals USA, Inc.
2026-04-06
Federal docket 1:26-cv-01839 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
DeCosta v. Teva Pharmaceuticals USA, Inc.
2026-04-05
Federal docket 1:26-cv-01824 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
De La Croix v. Teva Pharmaceuticals USA, Inc.
2026-04-03
Federal docket 1:26-cv-01804 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Napier v. Teva Pharmaceuticals USA, Inc.
2026-04-03
Federal docket 1:26-cv-01801 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Deluca v. Teva Pharmaceuticals USA, Inc.
2026-04-02
Federal docket 1:26-cv-01772 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Shaw v. Teva Pharmaceuticals USA, Inc.
2026-04-02
Federal docket 1:26-cv-01770 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Hakmon v. Teva Pharmaceuticals USA, Inc.
2026-04-02
Federal docket 1:26-cv-01771 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Templeton v. Teva Pharmaceuticals USA, Inc.
2026-04-01
Federal docket 1:26-cv-01760 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Knights v. Teva Pharmaceuticals USA, Inc.
2026-04-01
Federal docket 1:26-cv-01751 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Mazelon v. Teva Pharmaceuticals USA, Inc.
2026-04-01
Federal docket 1:26-cv-01748 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Bibby v. Teva Pharmaceuticals USA, Inc.
2026-03-31
Federal docket 1:26-cv-01738 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Bachman v. Teva Pharmaceuticals USA, Inc.
2026-03-30
Federal docket 1:26-cv-01689 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Tucker v. Teva Pharmaceuticals USA, Inc.
2026-03-27
Federal docket 1:26-cv-01650 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Liberatos v. Teva Pharmaceuticals USA, Inc.
2026-03-26
Federal docket 1:26-cv-01645 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Bozeman v. Teva Pharmaceuticals USA, Inc.
2026-03-26
Federal docket 1:26-cv-01643 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Fogle v. Teva Pharmaceuticals USA, Inc.
2026-03-26
Federal docket 1:26-cv-01641 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Williams v. Teva Pharmaceuticals USA, Inc.
2026-03-26
Federal docket 1:26-cv-01640 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Maxim v. Teva Pharmaceuticals USA, Inc.
2026-03-26
Federal docket 1:26-cv-01644 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Cutler v. Teva Pharmaceuticals USA, Inc.
2026-03-26
Federal docket 1:26-cv-01642 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Barriga v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01615 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Aaron v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01622 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Anderson v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01612 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Boldebuck v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01621 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Barnick v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01619 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Colley v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01609 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Potter v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01618 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Ruiz v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01620 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Abouetman v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01614 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Sodersten v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01610 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Schooling v. Teva Pharmaceuticals USA, Inc.
2026-03-25
Federal docket 1:26-cv-01613 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
Fellman v. Teva Pharmaceuticals USA, Inc.
2026-03-23
Federal docket 1:26-cv-01543 (gand); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
United States of America v. Teva Pharmaceuticals USA, Inc.
2022-07-08
Federal docket 1:22-cv-11107 (mad); matched party 'Teva Pharmaceuticals USA, Inc.'
View Source
EPA (Environmental Protection Agency)
3 records
epa_echo
1 records
fda
273 records
FDA Recall: Teva Pharmaceuticals USA, Inc — Class II
20260415
CGMP Deviations: use of an unapproved raw material | Product: Clonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Cover
View Source
FDA Drug Recall: Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20
2026-04-01
Class II — Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
View Source
FDA Drug Recall: Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10
2026-04-01
Class II — Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
View Source
FDA Drug Recall: Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30
2026-04-01
Class II — Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
View Source
FDA Drug Recall: Metoprolol Succinate Extended-Release Tablets, 50 mg, 100 tablets bottles (NDC:
2026-03-11
Class II — Failed Dissolution Specifications
View Source
FDA Drug Recall: Metoprolol Succinate Extended-Release Tablets, 25 mg, 100 tablets bottles (NDC:
2026-03-11
Class II — Failed Dissolution Specifications
View Source
FDA Drug Recall: Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx O
2026-03-11
Class II — Failed Dissolution Specifications
View Source
FDA Drug Recall: Metoprolol Succinate Extended-Release Tablets, Rx Only, 100 mg, 100 tablets bott
2026-03-11
Class II — Failed Dissolution Specifications
View Source
FDA Drug Recall: Carton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose p
2025-12-10
Class III — Defective Container - A defect in the side-seal which allows leakage of product.
View Source
FDA Drug Recall: Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg pe
2025-11-12
Class II — Subpotent drug; Clavulanate Potassium component
View Source
FDA Drug Recall: Prazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMA
2025-11-05
Class II — CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
View Source
FDA Drug Recall: Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMA
2025-11-05
Class II — CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
View Source
FDA Drug Recall: Prazosin Hydrochloride, Capsules, USP, 5 mg, Rx only, Distributed by TEVA PHARMA
2025-11-05
Class II — CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
View Source
FDA Drug Recall: Metoclopramide Tablets, USP 10 mg, 100-count bottle, Rx only, Manufactured in Cr
2025-07-02
Class II — Presence of foreign tablets/capsules.
View Source
FDA Drug Recall: Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe,
2025-02-12
Class II — Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
View Source
FDA Drug Recall: Testosterone Gel, 1.62%, (Alcohol 80% v/v), 30 unit-dose packets, Rx Only, Teva
2024-08-28
Class II — Superpotent Drug
View Source
FDA Drug Recall: Fludrocortisone Acetate Tablets, USP 0.1mg, Rx Only, 100 Tablets per bottle, Man
2024-07-24
Class II — Failed Impurities/Degradation Specifications: Product is being recalled due to API related substances and unknown impurities that are above the specification limits.
View Source
FDA Drug Recall: Amoxicillin and Clavulanate Potassium Tablets USP, Chewable 400mg/57mg, 20-count
2024-06-26
Class II — Subpotent Drug
View Source
FDA Drug Recall: Isotretinoin Capsules, USP 40mg, 30-count 3x10 blister packs per carton, Rx Only
2024-04-17
Class II — Superpotent Drug: The 3-month stability result for assay was found to be above specification limit
View Source
FDA Drug Recall: Tri-Lo-Sprintec (norgestimate and ethinyl estradiol) tablets USP - triphasic reg
2024-04-03
Class II — Failed Dissolution Specifications
View Source
FDA Drug Recall: Nortrel (norethindrone and ethinyl estradiol tablets USP) 0.5/35, packaged in ca
2024-02-21
Class III — Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
View Source
FDA Drug Recall: Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regime
2024-02-21
Class III — Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
View Source
FDA Drug Recall: Budesonide Extended-Release Tablets 9mg, 30-count bottle, Rx Only, Manufactured
2024-02-07
Class II — Failed Dissolution Specifications
View Source
FDA Drug Recall: Testosterone Gel, 1.62% CIII (Alcohol 80% v/v), packaged in 30 unit-dose packets
2023-12-06
Class III — OOS for viscosity
View Source
FDA Drug Recall: Sunitinib Malate Capsules, 12.5 mg, 28-count bottles, Rx only, Manufactured By:
2023-07-19
Class II — Failed Moisture Limits: Water (moisture) content above the approved product specifications.
View Source
FDA Drug Recall: Fentanyl Buccal Tablets CII, 600mcg, packaged in cartons of 28 Buccal Tablets (4
2023-05-31
Class III — Labeling: Incorrect or Missing Package Insert
View Source
FDA Drug Recall: Fentanyl Buccal Tablets CII, 400mcg, packaged in cartons of 28 Buccal Tablets (4
2023-05-31
Class III — Labeling: Incorrect or Missing Package Insert
View Source
FDA Drug Recall: Fentanyl Buccal Tablets CII, 200mcg, packaged in cartons of 28 Buccal Tablets (4
2023-05-31
Class III — Labeling: Incorrect or Missing Package Insert
View Source
FDA Drug Recall: Fentanyl Buccal Tablets CII, 800mcg, packaged in cartons of 28 Buccal Tablets (4
2023-05-31
Class III — Labeling: Incorrect or Missing Package Insert
View Source
FDA Drug Recall: Fentanyl Buccal Tablets CII, 100mcg, packaged in cartons of 28 Buccal Tablets (4
2023-05-31
Class III — Labeling: Incorrect or Missing Package Insert
View Source
FDA Drug Recall: Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 p
2023-04-12
Class III — Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.
View Source
FDA Drug Recall: Clear Eyes, Once Daily, Eye Allergy Itch Relief, olopatadine hydrochloride ophth
2023-03-22
Class II — Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.
View Source
FDA Drug Recall: Metformin hydrochloride Extended-Release Tablets, 1000 mg, 60-count bottle, RX o
2023-03-15
Class II — CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
View Source
FDA Drug Recall: Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate a
2022-09-21
Class II — Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product.
View Source
FDA Drug Recall: Neomycin Sulfate Tablets, USP 500 mg , 100-count bottles, Rx only, Distributed b
2022-09-07
Class II — CGMP Deviations: A foreign matter identified as teflon was found in the Active Pharmaceutical Ingredient (API) used in the manufacture of Neomycin Sulfate Tablets, USP 500 mg.
View Source
FDA Drug Recall: Azacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romani
2022-08-17
Class III — Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.
View Source
FDA Drug Recall: Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count b
2022-08-10
Class II — Failed Dissolution Specifications: below specification limits for dissolution.
View Source
FDA Drug Recall: Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count b
2022-08-10
Class II — Failed Dissolution Specifications: below specification limits for dissolution.
View Source
FDA Drug Recall: Testosterone Gel 1% (25mg testosterone/2.5g of gel) 2.5 g per unit dose, Rx Only
2022-08-03
Class II — Superpotent Drug: Out of specification assay result was obtained during stability testing.
View Source
FDA Drug Recall: Tretinoin Capsules, 10 mg, Rx Only, 100 capsules per bottle, Teva Pharmaceutical
2022-06-29
Class II — Failed Dissolution Specifications; Low Out of Specification (OOS) results for dissolution.
View Source
FDA Drug Recall: Alprostadil Injection USP 500 mcg/mL, 1 mL Single Dose Vial, 5 vials per Carton,
2022-06-15
Class III — Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during routine stability testing
View Source
FDA Drug Recall: Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in In
2022-06-08
Class I — Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.
View Source
FDA Drug Recall: Lidocaine 2.5% and Prilocaine 2.5% Cream, USP, packaged in a) 5 g tubes (NDC 05
2022-05-04
Class II — cGMP Deviations
View Source
FDA Drug Recall: IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL
2022-04-20
Class I — Presence of Particulate Matter: Product was found to contain silica and iron oxide
View Source
FDA Drug Recall: Mimvey (estradiol and norethindrone acetate tablets USP) 1 mg/0.5 mg, packaged i
2022-02-09
Class III — Mislabeling
View Source
FDA Drug Recall: Mimvey (estradiol and norethindrone acetate tablets USP), 1 mg/0.5 mg, packaged
2022-02-09
Class III — Mislabeling
View Source
FDA Drug Recall: Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/
2022-02-09
Class II — Failed Dissolution Specification: Dissolution results are below specification limits for the active ingredient
View Source
FDA Drug Recall: Tretinoin Capsules, 10 mg, 100 count bottle, Rx Only, Teva Pharmaceuticals USA,
2022-02-09
Class II — Failed Dissolution Specifications; Low Out of specification (OOS) results for dissolution.
View Source
FDA Drug Recall: Brinzolamide Ophthalmic Suspension, USP 1%, packaged as a)10 ml dropper bottles
2022-01-26
Class II — Defective Container: The notch in the cap that fits into the nozzle of the dropper could break off and block the dropper possibly resulting in the product not dispensing.
View Source
FDA Drug Recall: MethylPREDNISolone Acetate Injectable Suspension USP 400 mg/10mL (40mg/mL), 10 m
2022-01-19
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Norepinephrine Bitartrate Injection USP 4 mg/4 mL (1 mg/mL), 4 mL Single-Dose Vi
2022-01-19
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Penicillin V Potassium for Oral Solution, USP 125 mg (200,000 U) per 5 mL a) 100
2021-12-29
Class II — Subpotent
View Source
FDA Drug Recall: Cartia XT (Diltiazem Hydrochloride Extended-Release Capsules, USP) 120 mg, Rx On
2021-11-24
Class II — Labelling: Incorrect Exp. Date
View Source
FDA Drug Recall: Clonidine Transdermal System, USP 0.1 mg/day, 4 patches per carton, Rx only, Man
2021-11-24
Class III — Failed Impurities/Degradation Specifications
View Source
FDA Drug Recall: AirDuo Digihaler 55/14 (fluticasone propionate 55 mcg and salmeterol 14 mcg) Inh
2021-10-27
Class II — Subpotent drug: OOS results of Label Claimed Emitted Dose for salmeterol
View Source
FDA Drug Recall: AirDuo Digihaler 232/14 (fluticasone propionate 232 mcg and salmeterol 14 mcg) I
2021-10-27
Class II — Subpotent drug: OOS results of Label Claimed Emitted Dose for salmeterol
View Source
FDA Drug Recall: AirDuo Digihaler 113/14 (fluticasone propionate 113 mcg and salmeterol 14 mcg) I
2021-10-27
Class II — Subpotent drug: OOS results of Label Claimed Emitted Dose for salmeterol
View Source
FDA Drug Recall: AirDuo Digihaler 232/14 (fluticasone propionate 232 mcg and salmeterol 14 mcg) I
2021-10-27
Class II — Subpotent drug: OOS results of Label Claimed Emitted Dose for salmeterol
View Source
FDA Drug Recall: AirDuo Digihaler 113/14 (fluticasone propionate 113 mcg and salmeterol 14 mcg) I
2021-10-27
Class II — Subpotent drug: OOS results of Label Claimed Emitted Dose for salmeterol
View Source
FDA Drug Recall: Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx O
2021-09-08
Class II — CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.
View Source
FDA Drug Recall: Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx O
2021-09-08
Class II — CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.
View Source
FDA Drug Recall: Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx O
2021-09-08
Class II — CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.
View Source
FDA Drug Recall: Epoprostenol Sodium for Injection, 1.5 mg/vial, 10 mL vials, Rx only, Teva Pharm
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: DAUNOrubicin Hydrochloride Injection 20 mg/4mL, 4mL Single Dose vials, 10 in 1 c
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Leucovorin Calcium for Injection, USP 350 mg/vial, 17.5 mL single-use vials, Rx
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL, packaged in a) 1
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Norepinephrine Bitartrate Injection, USP 4 mg/4 mL, 4 mL single dose vials, pack
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Octreotide Acetate Injection 1000 mcg/5mL, 5 mL multi-dose vial, Rx only, Teva P
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Methylprednisolone Acetate Injectable Suspension USP, 80 mg/mL, packaged in a) 1
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Idarubicin Hydrochloride Injection 20 mg/20 mL, 20 mL single-dose vial, Rx only,
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Leucovorin Calcium for Injection, USP 350 mg/vial, 17.5 mL single-use vials, Rx
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Octreotide Acetate Injection 100 mcg/mL, 1 mL single-dose vial, Rx only, Teva Ph
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Octreotide Acetate Injection 50 mcg/mL, 1 mL single-dose vial, Rx only, Teva Pha
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Haloperidol Decanoate Injection 100 mg/mL, packaged in a) 1 mL single-dose vials
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Leucovorin Calcium for Injection, USP 100 mg/vial, 10 mL single-use vials, Rx on
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Adenosine Injection, USP, 60mg/20 mL (3 mg/mL), 20 mL single-dose vial, Rx only,
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Amikacin Sulfate Injection USP 1 gram/4mL (250mg/ML), 4 mL single-dose vials, Rx
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Alprostadil Injection USP, 500 mg/mL, 1 mL single dose, vials, 5 mL single use v
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Metoclopramide Injection USP, 10 mg/2mL (5 mg/mL) 2 mL single-use vial, Rx only,
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Vecuronium Bromide for Injection 10 mg, 10mL vial, Rx only, Teva Pharmaceuticals
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Adenosine Injection, USP, 60mg/20mL (3 mg/mL), 20 mL single-dose vial, Rx only,
2021-08-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Topotecan Injection 4 mg/4mL (1 mg/mL), Single-Dose vial, Teva Pharmaceuticals U
2021-07-14
Class I — Presence of Particulate Matter: Complaint received of a glass particle observed inside the vial. The vial was returned to Teva for further analysis where two other particulates were found an...
View Source
FDA Drug Recall: Haloperidol Decanoate Injection, USP 50 mg/mL, 1 mL Single Dose Vials, Rx Only,
2021-05-26
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Leucovorin Calcium for Injection, equivalent to leucovorin 350 mg/vial (20 mg/mL
2021-05-26
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 2 mL Single-Use Vial, Rx Onl
2021-05-26
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Haloperidol Decanoate Injection, USP 100 mg/mL, 1 mL Single Dose Vials, Rx Only,
2021-05-26
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL, 10 mL Multiple D
2021-05-26
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Romidepsin Injecton, 27.5 mg/5.5 mL (5 mg/mL) Rx Only, 5.5 ml vial, Teva Pharmac
2021-03-24
Class III — Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing.
View Source
FDA Drug Recall: Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 25x2mL Single Dose Vials, Rx
2021-03-10
Class II — Chemical contamination; Unknown brown residue adhering to the inside of one vial.
View Source
FDA Drug Recall: Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx on
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 2 mL Single-Use Vial NDC 070
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Sterile Diluent for Epoprostenol Sodium for Injection, 50 mL vial (NDC 0703-9258
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Desmopressin Acetate Injection USP, 4 mcg/mL, 1 mL Preserved Vial (NDC 0703-5051
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packa
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Vecuronium Bromide for Injection, 10 mg, 1 mg/mL when reconstituted to 10 mL, 10
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: MethyIPREDNISolone Acetate Injectable Suspension USP, 40 mg/mL, 1 mL Single-Do
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: MethyIPREDNISolone Acetate Injectable Suspension USP, 80 mg/mL, 1 mL Single-Dose
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Toposar (etoposide injection USP), 1 gram/50 mL (20 mg/mL), 50 mL Multiple-dose
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Epoprostenol Sodium for Injection, 0.5 mg/vial (500,000 ng), 1X10ML vial, Rx on
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/5 mL (80 mg/mL), 5
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 1
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Leucovorin Calcium for Injection, USP, 350 mg/vial, Rx only, labeled as a) Teva
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Leucovorin Calcium for Injection, USP, 100 mg/vial, Single-Dose Vial, Rx only, T
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: MethyIPREDNISolone Acetate Injectable Suspension USP, 200 mg/5 mL (0 mg/mL), 5 m
2021-03-03
Class II — Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile in...
View Source
FDA Drug Recall: Testosterone Gel 1%, 2.5 grams per unit dose, packaged in 2.5 gram Unit-Dose Pac
2020-11-25
Class III — Superpotent Drug: High out-of-specification assay results were obtained during stability testing.
View Source
FDA Drug Recall: Mesalamine Delayed-Release Tablets, USP 1.2 gram, 120 tablets per bottle, Rx Onl
2020-11-18
Class II — Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing.
View Source
FDA Drug Recall: Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal un
2020-10-07
Class II — Failed Stability Specifications: Below specification result for buprenorphine release rate.
View Source
FDA Drug Recall: Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For Ora
2020-09-16
Class II — CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
View Source
FDA Drug Recall: Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Ora
2020-09-16
Class II — CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
View Source
FDA Drug Recall: Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For Ora
2020-09-16
Class II — Sub-Potent Drug: Out of specification test results for potency (below specification).
View Source
FDA Drug Recall: Lidocaine Patch 5%, packaged in 30-count cartons, Rx only, Manufactured by: Acta
2020-08-19
Class II — Labeling: Incorrect or Missing Lot and/or Exp date on the individual transdermal pouches but not in the carton.
View Source
FDA Drug Recall: Metformin Hydrochloride Extended - Release Tablets, USP, 500 mg, a) 100 (NDC 620
2020-07-01
Class II — CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
View Source
FDA Drug Recall: Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, a) 100 (NDC 62037-
2020-07-01
Class II — CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
View Source
FDA Drug Recall: Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate a
2020-06-10
Class II — Some bottles may contain mixed strengths of the product.
View Source
FDA Drug Recall: Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate a
2020-06-10
Class II — Some bottles may contain mixed strengths of the product.
View Source
FDA Drug Recall: Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate a
2020-06-10
Class II — Some bottles may contain mixed strengths of the product.
View Source
FDA Drug Recall: Epinephrine Injection USP, 0.3 mg (Auto-Injector), 0.3 mg/ 0.3 mL pre-filled syr
2020-05-13
Class II — CGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-marketed lot number that shares the same component.
View Source
FDA Drug Recall: LOSARTAN POTASSIUM TABLETS, USP 50 mg, Bulk, Rx only, For Further Manufacturing
2020-04-15
Class II — CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
View Source
FDA Drug Recall: LOSARTAN POTASSIUM TABLETS, USP 100 mg, Bulk, Rx only, For Further Manufacturing
2020-04-15
Class II — CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
View Source
FDA Drug Recall: LOSARTAN POTASSIUM TABLETS, USP 25 mg, Bulk, Rx only, For Further Manufacturing,
2020-04-15
Class II — CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
View Source
FDA Drug Recall: Mesalamine Delayed-Release Tablets, USP, 1.2 gram, 120-count bottle, Rx Only, Ma
2020-03-11
Class II — Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing.
View Source
FDA Drug Recall: Tramadol Hydrochloride Tablets USP CIV, 50 mg, packaged in a) 100-count bottles
2020-02-26
Class III — Labeling: Incorrect package insert - Patient leaflets for the specified lots of unscored tablets contain language relative to a 25 mg dosing titration that necessitates the use of a scored...
View Source
FDA Drug Recall: Methylphenidate hydrochloride Extended-Release ablets USP (CII), 27 mg, 100-coun
2020-02-19
Class II — CGMP deviations: Product bottle may be absent of desiccant.
View Source
FDA Drug Recall: Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-coun
2020-02-19
Class II — CGMP deviations: Product bottle may be absent of desiccant.
View Source
FDA Drug Recall: Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by
2020-02-12
Class II — GMP Deviations: Product bottle may be absent of desiccant.
View Source
FDA Drug Recall: Desmopressin Acetate Tablets, 0.2 mg, 100-count bottle, Rx Only, Manufactured by
2020-02-12
Class II — GMP Deviations: Product bottle may be absent of desiccant.
View Source
FDA Drug Recall: Valganciclovir Hydrochloride for Oral Solution, 50 mg/mL, 100 mL (3.4 fl. oz.) b
2019-11-27
Class II — Presence of foreign substance: Brown/black particles found during stability testing.
View Source
FDA Drug Recall: Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30 count b
2019-10-16
Class III — GMP Deviation: lot not intended for commercial distribution.
View Source
FDA Drug Recall: LOSARTAN POTASSIUM 50 mg TABLET BULK 90 count bottles and 1000 count bottles, N
2019-07-17
Class II — CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
View Source
FDA Drug Recall: LOSARTAN POTASSIUM 100 mg TABLET BULK 90 count bottles, NDC 00591-3747-00
2019-07-17
Class II — CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
View Source
FDA Drug Recall: Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bot
2019-04-24
Class II — Subpotent Product: assay results for Amoxicillin were below the specification limits.
View Source
FDA Drug Recall: Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg, 100 tablets (
2019-03-27
Class III — Subpotent Drug.
View Source
FDA Drug Recall: Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 40 mg/25 mg, packaged in a
2019-01-23
Class II — Failed dissolution specifications
View Source
FDA Drug Recall: Amlodipine and Valsartan Tablets 5 mg/160 mg, (a) 30-count bottles (NDC 0093-769
2018-12-19
Class II — CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
View Source
FDA Drug Recall: Amlodipine and Valsartan Tablets 5 mg/320 mg, (a) 30-count bottles (NDC 0093-769
2018-12-19
Class II — CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
View Source
FDA Drug Recall: Amlodipine and Valsartan Tablets 10 mg/320 mg (a) 30-count bottles (NDC 0093-76
2018-12-19
Class II — CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
View Source
FDA Drug Recall: Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg, (a)
2018-12-19
Class II — CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
View Source
FDA Drug Recall: Amlodipine and Valsartan Tablets 10 mg/160 mg, (a) 30-count bottles (NDC 0093-79
2018-12-19
Class II — CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
View Source
FDA Drug Recall: Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg, (a)
2018-12-19
Class II — CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
View Source
FDA Drug Recall: Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg, (a)
2018-12-19
Class II — CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
View Source
FDA Drug Recall: Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg, (a
2018-12-19
Class II — CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
View Source
FDA Drug Recall: Alprostadil Injection USP 500 micrograms/mL 1 mL single use vial, 5 vials per ca
2018-11-21
Class II — Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during routine stability testing
View Source
FDA Drug Recall: Paliperidone Extended Release Tablets 9 mg, packaged in a) 30-count bottle(NDC 0
2018-10-31
Class II — Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.
View Source
FDA Drug Recall: Metoprolol Succinate Extended Release Tablets, USP 50 mg, 100-count bottle, Rx o
2018-10-31
Class II — Failed dissolution specifications: Out-of-Specification dissolution test result obtained during routine stability testing.
View Source
FDA Drug Recall: Metformin Hydrochloride Extended Release Tablets, 500 mg, 100-count bottle, Rx o
2018-10-31
Class II — Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.
View Source
FDA Drug Recall: Paliperidone Extended Release Tablets 3 mg, packaged in a) 30-count bottle(NDC 0
2018-10-31
Class II — Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.
View Source
FDA Drug Recall: Fortamet (metformin HCl) extended release tablets, 1000 mg, 60-count bottle, Rx
2018-10-31
Class II — Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.
View Source
FDA Drug Recall: Metformin Hydrochloride Extended Release Tablets 1000 mg, 60-count bottle, Rx on
2018-10-31
Class II — Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.
View Source
FDA Drug Recall: PIO&METFORMIN 15/1000 mg Tab 1 (Pioglitazone and Metformin XT) tablets, Takeda B
2018-10-31
Class II — Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.
View Source
FDA Drug Recall: Metformin Hydrochloride Extended Release Tablets 1000 mg, 90-count bottle, Rx on
2018-10-31
Class II — Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.
View Source
FDA Drug Recall: Clonazepam Orally Disintegrating Tablets USP, 2 mg., 60-count carton. RX only. T
2018-10-24
Class II — Failed Stability Specifications: Out-of-specification test result for water content obtained during routine stability testing.
View Source
FDA Drug Recall: Clozapine Orally Disintegrating Tablets, 12.5 mg, 100-count bottles, Rx only, Te
2018-10-10
Class II — Failed Disintegration Specifications: Out-of-specification disintegration test result obtained during routine stability testing.
View Source
FDA Drug Recall: Omega-3-Acid Ethyl Esters Capsules USP, 1 gram* 120-count bottle Rx Only. Manuf
2018-08-15
Class II — API material used in the manufacturing of the product did not receive regulatory approval prior to release.
View Source
FDA Drug Recall: Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/12.5 mg tablets, US
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Valsartan Tablets, USP 160 mg, 90-count bottle (NDC 0591-2169-19), 1000-count bo
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/25 mg tablets, USP
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Valsartan Tablets, USP 320 mg, 90-count bottle (NDC 0591-2170-19), 500-count bot
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 80 mg/12.5 mg tablets, 90
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Valsartan Tablets, USP 40 mg, 30-count bottle (NDC 0591-2167-30), 90-count bottl
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Valsartan Tablets, USP 80 mg, 90-count bottle (NDC 0591-2168-19), 1000-count bot
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 320 mg/12.5 mg tablets, US
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 320 mg/25 mg tablets, USP,
2018-08-01
Class II — CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
View Source
FDA Drug Recall: Fluocinolone Acetonide Topical Solution, USP, 0.01%, 60 mL bottle, Rx Only, Man
2018-07-18
Class II — Failed Impurities and Degradation Specifications and Subpotent Drug: out-of-specification (OOS) test results for below assay and above specification for degradants.
View Source
FDA Drug Recall: Lidocaine Patch 5% (700 mg) ,(NDC 0591-3525-11), 30 envelopes containing 1 patch
2018-05-30
Class III — Failed Stability Specifications
View Source
FDA Drug Recall: Estradiol Vaginal Inserts, USP 10 mcg, packaged in a) 8 inserts/carton (NDC 0093
2018-03-28
Class II — Defective Container: This recall is being initiated due to product complaints regarding difficulty in dispensing the tablet from the applicator.
View Source
FDA Drug Recall: Fluoxetine Tablets USP, 10 mg, 30-count bottle, Rx only, Manufactured in Israel
2018-02-21
Class III — Failed impurities/ degradation specifications: Teva Pharmaceuticals USA, Inc. is voluntarily recalling all lots within expiry due to out of specification (OOS) test result for the lactosid...
View Source
FDA Drug Recall: Fentanyl Transdermal System. 25 mcg/h, packaged in 5 pouch system cartons (NDC 0
2018-02-14
Class III — Failed Impurities/Degradation Specifications: Fentanyl-n-Oxide (FNO) degradant exceeding the specification limits
View Source
FDA Drug Recall: Fentanyl Transdermal System, 100 mcg/h, packaged in 5 pouch system (NDC 0591-321
2018-02-14
Class III — Failed Impurities/Degradation Specifications: Fentanyl-n-Oxide (FNO) degradant exceeding the specification limits
View Source
FDA Drug Recall: Fentanyl Transdermal System, 50 mcg/h, packaged in 5 pouch system cartons (NDC 0
2018-02-14
Class III — Failed Impurities/Degradation Specifications: Fentanyl-n-Oxide (FNO) degradant exceeding the specification limits
View Source
FDA Drug Recall: Fentanyl Transdermal System. 75 mcg/h, packaged in 5 pouch system (NDC 0591-3213
2018-02-14
Class III — Failed Impurities/Degradation Specifications: Fentanyl-n-Oxide (FNO) degradant exceeding the specification limits
View Source
FDA Drug Recall: Moexipril Hydrochloride and Hydrocholorothiazide Tablets USP, 7.5 mg/12.5 mg, 10
2018-01-17
Class II — Failed Impurities/Degradation Specifications: High out of specification test result for the Moexipril Diketopiperazine impurity was obtained during routine stability testing.
View Source
FDA Drug Recall: Amethyst (Levonorgestrel and Ethinyl Estradiol Tablets USP, 90mcg/20mcg), 28 ta
2017-12-27
Class II — Labeling: Incorrect Instructions. "TABLETS IN WEEK 4 ARE INACTIVE" printed on the blister foil and package insert, however,all tablets are active.
View Source
FDA Drug Recall: Penicillin V Potassium for Oral Solution, USP, 125 mg (200,000 U) per 5 mL, 100
2017-12-20
Class III — Failed Impurities/Degradation Specifications: high out of specification test results obtained for individual and total impurities.
View Source
FDA Drug Recall: Clozapine Tablets USP, 100 mg, 500 count bottles, Rx only, Manufactured in Israe
2017-12-06
Class II — Failed Tablet/Capsule Specifications; potential presence of broken tablets.
View Source
FDA Drug Recall: Dutasteride and Tamsulosin HCl Capsules, 0.5 mg/ 0.4 mg, packaged in a) 30-count
2017-11-08
Class II — Failed dissolution specifications; all lots within expiry are being recalled due to out of specification dissolution results.
View Source
FDA Drug Recall: Methylphenidate Hydrochloride Tablets USP, 20 mg, 100-count bottles, Rx only, Ma
2017-11-01
Class III — Failed Dissolution Specifications: Low out of specification results for dissolution.
View Source
FDA Drug Recall: Acarbose Tablets, 25 mg, 100-count bottle, Rx only, Manufactured by: Arrow Pharm
2017-10-04
Class II — Labeling: Incorrect or Missing Lot and/or Exp Date: An incorrect expiration date of July 2018 is printed on the product labeling rather than the correct expiration date of July 2017.
View Source
FDA Drug Recall: Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-u
2017-08-16
Class III — Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
View Source
FDA Drug Recall: Famotidine Tablets USP, 20 mg, 100 count bottles, Rx only, Manufactured For: TE
2017-08-09
Class II — Failed Tablet/Capsule Specification; out of specification for tablet weight
View Source
FDA Drug Recall: Albuterol Sulfate Inhalation Solution, 0.021% (0.63 mg/3mL), packaged in 5 pouch
2017-08-09
Class III — Failed Impurities/Degradation Specifications: high out of specification results for related compound D.
View Source
FDA Drug Recall: Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle
2017-07-26
Class III — Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.
View Source
FDA Drug Recall: Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg 30 tablets per Bottle, R
2017-07-26
Class III — Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.
View Source
FDA Drug Recall: Clozapine Tablets USP, 25 mg, 100-count bottle (NDC 0093-4359-01), 500- count bo
2017-05-17
Class II — Microbial Contamination of Non-Sterile Products
View Source
FDA Drug Recall: PrednisoLONE Oral Solution USP, 15 mg/5mL, alcohol content: 5%(v/v) 240 mL bott
2017-05-17
Class III — Failed Stability Specifications
View Source
FDA Drug Recall: Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles,
2017-03-22
Class II — Failed Impurities/Degradation Specifications
View Source
FDA Drug Recall: Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per bli
2017-03-15
Class III — Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.
View Source
FDA Drug Recall: Mimvey Lo (estradiol and norethindrone acetate tablets USP), 0.5 mg/0.1 mg, 28 t
2017-02-22
Class II — Failed Impurities/Degradation Specifications: out of specification test results for the norethindrone impurity.
View Source
FDA Drug Recall: Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in a 100 mL bottl
2017-02-01
Class II — Subpotency: due to a low, out of specification test result for assay during stability testing.
View Source
FDA Drug Recall: Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per bli
2017-01-25
Class III — Failed Dissolution Specifications
View Source
FDA Drug Recall: Qnasl (beclomethasone dipropionate) Nasal Aerosol 40 Mcg, 60 Metered Sprays, Rx
2016-12-14
Class III — Failed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.
View Source
FDA Drug Recall: Qnasl (beclomethasone dipropionate) Nasal Aerosol 80 Mcg, 50 Metered Sprays, Rx
2016-12-14
Class III — Failed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.
View Source
FDA Drug Recall: PARICALCITOL Capsules, 2 mcg, 30-count bottles, Rx only, Manufactured By: Pharma
2016-10-26
Class III — Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.
View Source
FDA Drug Recall: PARICALCITOL Capsules, 4 mcg, 30-count bottles, Rx only, Manufactured By: Pharma
2016-10-26
Class III — Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.
View Source
FDA Drug Recall: PARICALCITOL Capsules, 1 mcg, 30-count bottles, Rx only, Manufactured By: Pharma
2016-10-26
Class III — Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.
View Source
FDA Drug Recall: Amikacin Sulfate Injection, USP, 500 mg/2 mL (250 mg/mL) Rx Only, Manufactured i
2016-10-19
Class II — CGMP Deviations
View Source
FDA Drug Recall: mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple
2016-10-19
Class III — Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.
View Source
FDA Drug Recall: Amikacin Sulfate Injection, USP, 1 gm/4 mL (250 mg/mL) Rx Only, Manufactured in
2016-10-19
Class II — CGMP Deviations
View Source
FDA Drug Recall: Amikacin Sulfate injection USP,1 gm/4 mL (250 mg/mL) 4mL vial, Rx only, Manufac
2016-06-01
Class I — Presence of Particulate Matter: particulate matter identified as glass in one vial.
View Source
FDA Drug Recall: NABUMETONE Tablets USP, 750 mg, 100 count bottle,Teva Pharmaceutical Industries
2016-03-23
Class III — Labeling: Not Elsewhere Classified: Lack of leaflets and approved labels on bottles.
View Source
FDA Drug Recall: Paricalcitol Capsules, 1 mcg, 30 tablets per Bottle, Rx Only, Manufactured By: P
2016-03-23
Class II — Failed Impurities/Degradation Specifications: Out of specification test results for impurities during stability testing.
View Source
FDA Drug Recall: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE A
2016-01-20
Class II — Failed Impurities/Degradation Specifications: High out of specification test result for impurities during stability testing.
View Source
FDA Drug Recall: ADRUCIL (fluorouracil injection, USP), 5 g/100 mL (50 mg/mL) glass vials, 5 x 10
2015-09-02
Class I — Presence of Particulate Matter: silcone rubber and fluorouracil crystals found floating in solution
View Source
FDA Drug Recall: Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate a
2015-08-12
Class II — Failed Impurities/Degradation Specifications: out of specification for unknown impurity
View Source
FDA Drug Recall: Adrucil (fluorouracil injection, USP) Pharmacy Bulk Package Not for Direct Infus
2015-07-15
Class I — Presence of Particulate Matter: Black particulate matter was identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals.
View Source
FDA Drug Recall: Zebeta¿ (bisoprolol fumarate), tablets, 10mg, 30-count bottle, Rx only, Manufact
2015-06-10
Class II — Failed Dissolution Specifications: OOS result during stability testing
View Source
FDA Drug Recall: QVAR (beclomethasone dipropionate HFA 40 mcg), 40 mcg Inhalation Aerosol, For Or
2015-06-03
Class III — Failed Impurities/Degradation Specifications: out of specification test results for an impurity during stability testing.
View Source
FDA Drug Recall: Fluoxetine Capsules USP, 20 mg, packaged in a) 500-count bottles (NDC 50111-648-
2015-05-06
Class II — Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological Concern (TTC) calculation for the imp...
View Source
FDA Drug Recall: Fluoxetine Capsules USP, 10 mg, in 100-count bottles, Rx only, Manufactured by P
2015-05-06
Class II — Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological Concern (TTC) calculation for the imp...
View Source
FDA Drug Recall: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE A
2014-11-05
Class II — Failed Impurities/Degradation Specifications: Out of specification for unknown impurities.
View Source
FDA Drug Recall: Carbidopa and Levodopa Tablets USP, 25mg/100mg, 1000 count bottle, Rx only, Man
2014-08-20
Class II — Failed Tablet/Capsule Specifications: Teva is recalling one lot of Carbidopa and Levodopa Tablets USP, 25mg/100mg due to the potential for superpotent tablets.
View Source
FDA Drug Recall: triple therapy, LANSOPRAZOLE DR Capsules USP 30mg, CLARITHROMYCIN Tablets USP 50
2014-08-06
Class II — Failed Impurities/Degradation Specifications: This recall is due to out of specification for impurities test results obtained during stability testing for Lansoprazole.
View Source
FDA Drug Recall: Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 m
2014-07-23
Class III — Failed Impurities/Degradation Specifications: out of specification impurity test results.
View Source
FDA Drug Recall: Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic
2014-07-23
Class III — Failed Impurities/Degradation Specifications: out of specification impurity test results.
View Source
FDA Drug Recall: Kariva (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets 0.15 mg/
2014-07-23
Class III — Failed Impurities/Degradation Specifications: out of specification impurity test results.
View Source
FDA Drug Recall: Mircette (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets 0.15 mg
2014-07-23
Class III — Failed Impurities/Degradation Specifications: out of specification impurity test results.
View Source
FDA Drug Recall: Fluvastatin Capsules USP, 20 mg, Rx Only, 30-count bottle, manufactured for Teva
2014-07-16
Class II — Failed Tablet/Capsule Specifications: Teva Pharmaceuticals USA, Inc. is voluntarily recalling one lot of Fluvastatin Capsules USP, 20 mg due to a customer complaint trend regarding capsule ...
View Source
FDA Drug Recall: Dextroamphetamine Sulfate Tablets, USP, 10 mg, 100-count bottles, Rx only, Barr
2014-07-02
Class II — Failed Impurities/Degradation Specifications: this product is being recalled due to an out of specification test result for impurities during stability testing.
View Source
FDA Drug Recall: ParaGard T 380A - Intrauterine Copper Contraceptive, 176 mg of copper wire, Dura
2014-06-04
Class II — Non-sterility: due to a failed sterility test
View Source
FDA Drug Recall: BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 8 mg, 30-count bottles, Rx only,
2014-05-28
Class II — Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.
View Source
FDA Drug Recall: QVAR¿ (beclomethasone dipropionate HFA), 80mcg Inhalation Aerosol, 50 metered in
2014-05-28
Class II — Defective Delivery System; defective valve
View Source
FDA Drug Recall: BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 2 mg, 30-count bottles, Rx only,
2014-05-28
Class II — Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.
View Source
FDA Drug Recall: INDOMETHACIN Capsules USP, 25 mg 100 count bottle, Rx only , Manufactured In IND
2014-05-21
Class II — CGMP Deviations; laboratory testing was not followed in accordance with GMP requirements
View Source
FDA Drug Recall: METHYLDOPA Tablets USP, 500 mg, 100 count bottle, Rx only, Manufactured In INDIA
2014-05-21
Class II — CGMP Deviations; laboratory testing was not followed in accordance with GMP requirements
View Source
FDA Drug Recall: GLYBURIDE and METFORMIN HYDROCHLORIDE Tablets USP, 5mg/500mg, 500 count bottle,
2014-05-21
Class II — CGMP Deviations; laboratory testing was not followed in accordance with GMP requirements
View Source
FDA Drug Recall: INDOMETHACIN Capsules USP, 50 mg, a) 100 count bottle, (NDC 0093-4030-01), b) 50
2014-05-21
Class II — CGMP Deviations; laboratory testing was not followed in accordance with GMP requirements.
View Source
FDA Drug Recall: Fluoxetine Capsules USP, 20 mg, packaged in a) 100-count bottles (NDC 50111-648-
2014-05-07
Class II — Chemical Contamination: Recall due to a customer complaint trend regarding capsule odor.
View Source
FDA Drug Recall: Fluoxetine Capsules USP, 10 mg, 100-count bottles, Rx only, Manufactured in Pola
2014-05-07
Class II — Chemical Contamination: Recall due to a customer complaint trend regarding capsule odor.
View Source
FDA Drug Recall: Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 30 Capsules per Bottle
2014-04-09
Class II — Failed Tablet/Capsule Specifications: Teva Pharmaceuticals USA, is voluntarily recalling certain lots of Duloxetine DR Capsules USP, 20 mg, 30 mg & 60 mg due to a customer complaint trend r...
View Source
FDA Drug Recall: Duloxetine Delayed-Release Capsules, USP, 20 mg, Rx Only, 60 capsules per Bottle
2014-04-09
Class II — Failed Tablet/Capsule Specifications: Teva Pharmaceuticals USA, is voluntarily recalling certain lots of Duloxetine DR Capsules USP, 20 mg, 30 mg & 60 mg due to a customer complaint trend r...
View Source
FDA Drug Recall: Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 30 Capsules per Bottle
2014-04-09
Class II — Failed Tablet/Capsule Specifications: Teva Pharmaceuticals USA, is voluntarily recalling certain lots of Duloxetine DR Capsules USP, 20 mg, 30 mg & 60 mg due to a customer complaint trend r...
View Source
FDA Drug Recall: QVAR¿ (beclomethasone dipropionate HFA), C4 INHALATION AEROSOL in Aluminum Cylin
2014-04-09
Class III — Failed Impurity/Degradation Specification; for 17-BMP at the 9 and 18 month stability time point
View Source
FDA Drug Recall: Teva Hydroxyzine Pamoate Capsules, USP, 100 mg, 100- count bottle,Rx only, Distr
2014-03-12
Class II — CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 100 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.
View Source
FDA Drug Recall: Teva Dextroamphetamine Saccharate, Amphetamine Asparate, Dextroamphetamine Sulfa
2014-03-12
Class II — CGMP Deviations: Dextroamphetamine Saccharate, Amphetamine Asparate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, CII, 10 mg were manufactured using unapproved material: the f...
View Source
FDA Drug Recall: Teva Ethambutol Hydrochloride Tablets, USP, 400 mg, 100- count bottle, Rx Only,D
2014-03-12
Class II — CGMP Deviations: Ethambutol Hydrochloride Tablets, USP, 400 mg were manufactured using unapproved material: the incorrect gelatin excipient than specified in the product formulation.
View Source
FDA Drug Recall: Teva Hydroxyzine Pamoate Capsules, USP, 25 mg, 100- count bottle, Rx Only,Distri
2014-03-12
Class II — CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 25 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.
View Source
FDA Drug Recall: Valacyclovir Hydrochloride Tablets, 1 g, 30 count bottle, Rx only manufactured i
2014-02-12
Class II — Presence of Foreign Tablets/Capsules: Potential of Pravastatin tablet fragments in bottles of Valacyclovir 1 gm Tablets.
View Source
FDA Drug Recall: Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in
2014-02-12
Class II — Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.
View Source
FDA Drug Recall: Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufa
2014-02-12
Class II — Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.
View Source
FDA Drug Recall: Fluconazole Oral Suspension, 10 mg/mL, 35 ml bottle, RX only, Mfd by Cipla, Ltd.
2014-01-29
Class III — Failed Stability Specifications: this product is below specification for preservative content.
View Source
FDA Drug Recall: Daunorubicin Hydrochloride Injection, 20 mg/4 mL (5 mg/mL), 4 mL Single Dose Via
2014-01-08
Class II — Presence of Precipitate; precipitation of drug product
View Source
FDA Drug Recall: Niacin Extended Release Tablets, USP, 500 mg, 90 count bottle, Rx Only, Teva Pha
2014-01-08
Class II — Failed Tablet/Capsule Specifications: There is a potential for broken tablets.
View Source
FDA Drug Recall: Qnasl (beclomethasone dipropionate) Nasal Aerosol, 80 mcg per spray, 120 metered
2014-01-01
Class III — Defective Delivery System: There is a potential for some units in certain lots of Qnasl Nasal Aerosol 80 mcg metered spray to have clogged stem valves.
View Source
FDA Drug Recall: Copaxone (glatiramer acetate injection), 20 mg/1 mL, 1 mL pre-filled syringe, pa
2013-11-27
Class II — Presence of Particulate Matter: A foreign particle found in a pre-filled syringe was reported through a consumer complaint about a pre-filled syringe.
View Source
FDA Drug Recall: CARBOplatin Injection, 600 mg/60ml, MultiDose, Rx only, Teva Parenteral Medicine
2013-09-11
Class II — Lack of Assurance of Sterility: The required reduction of endotoxin was not met during the annual revalidation of the vial washer.
View Source
FDA Drug Recall: Propranolol Hydrochloride Tablets, USP, 10 mg, Rx Only, 1000 count bottles, Man
2013-09-04
Class II — Failed Tablet/Capsule Specification: Teva is recalling certain lots of Propanolol HCl Tablets, 10 mg due to the potential of some tablets not conforming to weight specification.
View Source
FDA Drug Recall: Terazosin Hydrochloride Capsules,10 mg, 100-count bottle, Rx only, Manufactured
2013-08-14
Class II — Labeling -label error on declared strength: unopened, sealed bottle of Terazosin Hydrochloride (HCl) 10mg Capsules contained Terazosin HCl 5 mg Capsules
View Source
FDA Drug Recall: Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count b
2013-08-14
Class II — Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.
View Source
FDA Drug Recall: Methylphenidate Hydrochloride Extended-Release Capsules (LA), 20 mg, 100 count b
2013-08-14
Class II — Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.
View Source
FDA Drug Recall: Methylphenidate Hydrochloride Extended-Release Capsules (LA), 30 mg, 100 count b
2013-08-14
Class II — Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.
View Source
FDA Drug Recall: Amoxicillin for Oral Suspension, USP 200 mg/5 mL, a) 75 mL bottle NDC 0093-4160-
2013-07-24
Class III — Discoloration: This recall is being carried out due to an orange to brown discolored Amoxicillin powder on the inner foil seal of the bottles. This is an expansion of RES 65050.
View Source
FDA Drug Recall: Errin (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tabl
2013-07-17
Class III — Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
View Source
FDA Drug Recall: Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP an
2013-07-17
Class III — Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
View Source
FDA Drug Recall: Lessina(R) (Levonorgestrel and ethinyl estradiol tablets, USP) 0.1 mg/0.02 mg, 2
2013-07-17
Class III — Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
View Source
FDA Drug Recall: Camila (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tab
2013-07-17
Class III — Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
View Source
FDA Drug Recall: Jolessa(R) (levonorgestrel/ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 91 d
2013-07-17
Class III — Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
View Source
FDA Drug Recall: Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg,
2013-07-17
Class III — Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
View Source
FDA Drug Recall: Actiq (oral transmucosal fentanyl citrate) 200 mcg, lozenge on a stick, a)Single
2013-06-26
Class II — Failed Dissolution Specification; during stability testing
View Source
FDA Drug Recall: Amoxicillin for Oral Suspension, USP 400mg/5mL, NDC 0093-4161-78 (75ml) and 0093
2013-06-19
Class III — Discoloration: This recall is being carried out due to a yellow to brown discolored Amoxicillin powder on the inner foil seal of the bottles.
View Source
FDA Drug Recall: Disulfiram Tablets USP 250 mg, 100 tablet bottle, Rx only, Manufactured for TEVA
2013-06-12
Class III — CGMP Deviation; cotton coil is missing in some packaged bottles
View Source
FDA Drug Recall: Seasonale(R) (Levonorgestrel/Ethinyl Estradiol Tablets), 0.15 mg/0.03 mg, 3 exte
2013-06-05
Class III — Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing
View Source
FDA Drug Recall: Camrese(TM) (Levonorgestrel/Ethinyl Estradiol Tablets), 0.15 mg/0.03 mg and Ethi
2013-06-05
Class III — Failed Impurity/Degradation Specifications; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing
View Source
FDA Drug Recall: Copaxone (glatiramer acetate injection), 20 mg/1 mL, packaged in 30 single use P
2013-04-24
Class II — Presence of Foreign Substance: Product is being recalled due to receiving an elevated number of patient complaints related to a visible presence of medical grade silicone oil essential to t...
View Source
FDA Drug Recall: Jolessa (levonorgestrel/ethinyl estradiol) Tablets, 0.15 mg/0.03 mg, 91-count ta
2013-04-17
Class III — Failed Tablet/Capsule Specifications: This recall is being carried out due to an out of specification result for appearance.
View Source
FDA Drug Recall: Cefdinir for Oral Suspension, 125 mg/5 mL, packaged in a) 60 mL bottle (NDC 0093
2013-04-17
Class II — Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.
View Source
FDA Drug Recall: Portia (levonorgestrel and ethinyl estradiol) Tablets, USP, 0.15 mg/0.03 mg, 28-
2013-04-17
Class III — Failed Tablet/Capsule Specifications: This recall is being carried out due to an out of specification result for appearance.
View Source
FDA Drug Recall: CLONAZEPAM ORALLY DISINTERGRATING Tablets, USP, 0.5 mg, 60 tablets (10 blister
2013-04-10
Class II — Failed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result for content uniformity.
View Source
FDA Drug Recall: Terazosin Hydrochloride Capsules, 2 mg, packaged in a) 100-count bottles (NDC 00
2013-03-20
Class II — Presence of Foreign Tablets/Capsules: Recall is being conducted due to a foreign capsule found in one bottle.
View Source
FDA Drug Recall: CABERGOLINE Tablets, 0.5 mg, RX only, 8 count bottles, Manufactured For: TEVA PH
2013-01-23
Class III — Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life
View Source
FDA Drug Recall: Copaxone (glatiramer acetate injection), 20mg/mL, 1 mL , Rx only, Marketed by:
2012-08-15
Class II — Presence of Foreign Substance: Recall is being initiated due to the presence of a foreign particle identified from a customer complaint.
View Source
FDA Drug Recall: Metoprolol Tartrate Tablets USP 50 mg, 1000 count bottle, Rx only, Manufactured
2012-07-11
Class II — Tablet Thickness: Potential for some tablets not conforming to weight specifications (under and over weight)
View Source
FDA Drug Recall: Zeosa (norethindrone and ethinyl estradiol tablets USP, (chewable), 0.4 mg/0.035
2012-07-04
Class II — Impurities/Degradation: This recall is being carried out due to the potential for some lots not meeting impurity specifications.
View Source
FDA Drug Recall: Mefloquine HCL Tablets, 250 mg, 5 tablets per blister pack; 5 Blister packs per
2012-07-04
Class II — Tablet Thickness: Product is being recalled due to the potential of being underweight or overweight.
View Source
FDA Drug Recall: Jolessa (levonorgestrel/ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, each Di
2012-06-27
Class III — Contraceptive Tablets Out of Sequence: This recall has been initiated due to the potential that some regimen packages may not contain placebo tablets.
View Source
fda_adverse
3 records
FDA AE Manufacturer: Teva Pharmaceuticals USA, Inc.
Drug adverse event reporter — Product: ACYCLOVIR
View Source
FDA AE Manufacturer: Teva Pharmaceuticals USA Inc.
Drug adverse event reporter — Product: DICLOFENAC EPOLAMINE
View Source
FDA AE Manufacturer: TEVA Pharmaceuticals USA Inc
Drug adverse event reporter — Product: GLYBURIDE
View Source
ftc_enforcement
1 records
Teva Pharmaceuticals USA, Inc., Plaintiff-Appellant, v. Pfizer, Inc., Defendant-Appellee (In the United States Court of Appeals for the Federal Circuit)
2005-02-11
FTC live enforcement action FY2005; matched respondent 'Teva Pharmaceuticals USA, Inc., Plaintiff-Appellant, v. Pfizer, Inc., Defendant-Appellee (In the United States Court of Appeals for the Federal ...
View Source
lobbying
6 records
Lobbying Client: TEVA PHARMACEUTICALS USA, INC.
Lobbied by FAEGRE DRINKER BIDDLE & REATH LLP — Pharmaceutical manufacturer
View Source
Lobbying Client: TEVA PHARMACEUTICALS USA, INC.
Lobbied by COLAS & ASSOCIATES, LLC — Drug manufacturer
View Source
Lobbying Client: TEVA PHARMACEUTICALS USA, INC.
Lobbied by FAEGRE DRINKER BIDDLE & REATH LLP — Pharmaceutical manufacturer
View Source
Lobbying Client: TEVA PHARMACEUTICALS USA, INC.
Lobbied by MR. DAVID FRIEDMAN — Pharmaceutical manufacturer.
View Source
Lobbying Client: TEVA PHARMACEUTICALS USA, INC.
Lobbied by TALLEY STRATEGIES LLC — Pharmaceutical company
View Source
ny_corps
1 records
NY Corp: TEVA PHARMACEUTICALS USA, INC.
2003-09-29
FOREIGN BUSINESS CORPORATION | County: Nassau | Jurisdiction: Delaware
View Source
Be informed when major changes happen on CFVA — new data sources, platform updates, critical enforcement alerts
No spam. Only major updates. Unsubscribe anytime.